waveRAPID® - The New Way of Measuring Kinetics
Official product launch
Introducing waveRAPID®, the new way of measuring kinetics to boost throughput. Instead of relying a titration series in conventional kinetics, waveRAPID injects a single concentration, pulsing the sample over the sensing surface at increasing durations. From a single well, kinetics can be derived: the on-rate, off-rate, affinity and Rmax. With no need for serial dilutions or DMSO corrections, set-up time is significantly reduced, runs are faster, and wells are freed up to run more samples.
Kinetics in hours instead of days
We have put together a fantastic line up of scientists from both industry and academia to join us on February 2nd, 2021 for an event full of webinars, a roundtable and much more.
CTO and Founder - Creoptix AG
Kaspar Cottier, PhD
Dr. Kaspar Cottier founded Creoptix in 2009 and since then is fully dedicated to push the technology from a research stage to a commercial success. Before Creoptix, Kaspar was at Optrel AG in Wattwil, Switzerland, where he first worked as Optics Engineer and Deputy Director R&D, and later as Director Operations responsible for production, supply chain and process engineering.
Kaspar obtained his diploma (M.Sc. degree) in micro-engineering with specialization in optics from the Swiss Federal Institute of Technology Lausanne (EPFL) and his PhD from the University of Neuchatel, Switzerland, on the topic of label-free waveguide-grating sensors.
CEO - leadXpro
Michael Hennig, PhD
Dr. Michael Hennig studied Physics and Biochemistry, received the Ph.D. in structural biology at EMBL Hamburg, and the Charité, Humboldt University Berlin, Germany. It followed two years postdoc work at the Biozentrum, University of Basel, Switzerland and 20 years of work in pharmaceutical industry at Roche, Basel, Switzerland. Finally, he was Global Head and Principle Leader of discovery technologies with responsibility for structure-based drug discovery, protein science, assay development and HTS, Roche corporate compound library, stem cell platform and analytical physical methods. In 2015, he co-founded leadXpro, a corporation dedicated to structure-based drug discovery for membrane protein targets (GPCR’s, Ion-channels, Transporter) and utilizing most advanced technologies such as the X-ray free electron laser (at PSI, SwissFEL) and cryo-electron microscopy (at University of Basel, cryo-EM) and biophysics methods such as provided by Creoptix.
Senior Scientist - leadXpro
Nicolas Bocquet, PhD
Nicolas holds a PhD degree in Neuroscience from the University Pierre et Marie Curie (Pasteur Institute) in Paris. After a postdoc at the Friedrich Miescher Institute for Biomedical Research in Basel, he joined Roche to work on the development of biophysical methods for membrane proteins. At leadXpro, he combines his expertise and experience to gather structural information and decipher ligand-binding mechanisms on membrane protein targets using grating-coupled interferometry (GCI) technology.
Professor of Biochemistry - University of Uppsala
Helena Danielson, PhD
Helena is a Professor of Biochemistry at Uppsala University in Sweden since 2002 and Chief Scientific Officer of Beactica AB. Specialist in enzymology and enzyme-based drug discovery with a focus on biomolecular interaction analysis for detailed studies of enzyme-inhibitor interactions and other important recognition processes in the life science area. The work has involved studies of a variety of enzymes, primarily proteases and polymerases from viruses and other infectious organisms, or involved in important disease processes. Extensive experience of the commercial drug discovery process through 20 years of collaborative research with partners in pharmaceutical and biotechnological industry.
CEO - 2bind
Thomas Schubert, PhD
Since 2013, Dr. Schubert is the CEO of 2bind - one of the leading service providers in the field of molecular interaction analyses based on the MST Technology. He received his degree as Betriebswirt (business economist) with main focus on strategic marketing, strategic management, personnel management and cost systems at the IWW (Institut für wirtschaftswissenschaftliche Forschung und Weiterbildung) in Hagen, Germany. In addition, he has an extensive background on biochemistry (epigenetics, influence of small RNAs on chromatin accessibility) gathered at the university of Regensburg.